title: [New physiopathological roles for the PLA2R1 receptor in cancer and membranous nephropathy].
abstract: PLA2R1 is a large transmembrane receptor of 180-kDa that belongs to the superfamily of C-type lectins. It was discovered because of its high affinity for secreted phospholipases A2 (sPLA2), enzymes that play a key role in lipid mediator synthesis. Early PLA2R1 physiological roles include the clearance of sPLA2 from the extracellular medium and/or promotion of their actions. Over the last four years, two independent studies suggested that PLA2R1 plays a role in cancer as a tumor gene suppressor and is the major target antigen of auto-immune antibodies involved in idiopathic membranous nephropathy, a severe human kidney disease. These novel findings shed light on PLA2R1 and pave the way for its use as a reliable biomarker and an attractive therapeutic target in these diseases.
authors.affiliation: Institut de pharmacologie moléculaire et cellulaire, CNRS et université de Nice-Sophia Antipolis UMR 7275, 660 route des lucioles, Sophia Antipolis, 06560 Valbonne, France.
authors.forename: Christophe A
authors.initials: CA
authors.lastname: Girard
authors.affiliation: Institut de pharmacologie moléculaire et cellulaire, CNRS et université de Nice-Sophia Antipolis UMR 7275, 660 route des lucioles, Sophia Antipolis, 06560 Valbonne, France - Service de néphrologie, CHU hôpital Pasteur, université de Nice-Sophia Antipolis, Nice, France.
authors.forename: Barbara
authors.initials: B
authors.lastname: Seitz-Polski
authors.affiliation: Institut de pharmacologie moléculaire et cellulaire, CNRS et université de Nice-Sophia Antipolis UMR 7275, 660 route des lucioles, Sophia Antipolis, 06560 Valbonne, France.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Dolla
authors.affiliation: Inserm U1052, centre de recherche en cancérologie de Lyon, CNRS et université de Lyon, UMR 5286, centre Léon Bérard, 69373 Lyon, France.
authors.forename: Arnaud
authors.initials: A
authors.lastname: Augert
authors.affiliation: Inserm U1052, centre de recherche en cancérologie de Lyon, CNRS et université de Lyon, UMR 5286, centre Léon Bérard, 69373 Lyon, France.
authors.forename: David
authors.initials: D
authors.lastname: Vindrieux
authors.affiliation: Inserm U1052, centre de recherche en cancérologie de Lyon, CNRS et université de Lyon, UMR 5286, centre Léon Bérard, 69373 Lyon, France.
authors.forename: David
authors.initials: D
authors.lastname: Bernard
authors.affiliation: Institut de pharmacologie moléculaire et cellulaire, CNRS et université de Nice-Sophia Antipolis UMR 7275, 660 route des lucioles, Sophia Antipolis, 06560 Valbonne, France.
authors.forename: Gérard
authors.initials: G
authors.lastname: Lambeau
mesh_terms: D000818:Animals; D001323:Autoantibodies / Q000502:physiology; D016147:Genes, Tumor Suppressor; D015433:Glomerulonephritis, Membranous / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000235:genetics; D009369:Neoplasms / Q000235:genetics* / Q000378:metabolism; D054467:Phospholipases A2 / Q000378:metabolism; D054507:Receptors, Phospholipase A2 / Q000737:chemistry / Q000502:physiology*
chemical_list: D001323:Autoantibodies; C516360:PLA2R1 protein, human; D054507:Receptors, Phospholipase A2; D054467:Phospholipases A2